Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 2011

View Archived Issues

Interim first-in-human data released on two c-Met inhibitors

Trial determines phase II doses of ixabepilone/cisplatin combination regimen in NSCLC

Halozyme discloses clinical results on new Herceptin formulation

Pulmonary Fibrosis Foundation to fund independent evaluation of Compugen's candidate for IPF

Orantinib advances through studies in NSCLC and breast cancer

U.S. universities assess CDME in model of cystinuria

Analyses focus on cardiovascular risk with naltrexone/bupropion

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Phase I study of PPI-668 commences

CSIR presents new antitumor agents

Takeda commences international phase III program for TAK-875

Lpath begins dosing in second proof-of-concept iSONEP trial

Studies confirm efficacy of Transcend-trastuzumab conjugate in HER2-positive breast cancer

Encore Therapeutics completes proof-of-concept study of ETI-511

Novel vitamin D receptor ligands synthesized at WARF

FDA clears IsoAmp HSV assay

Nile Therapeutics completes dosing in subcutaneous cenderitide trial

Phase I MultiStem study advances

Actelion Pharmaceuticals reports new prostanoid DP2 receptor antagonists

FDA approves MethylGene's IND for new study of antifungal product candidate

Lux Biosciences withdraws Luveniq MAA

Almirall and Lundbeck enter agreement to copromote escitalopram

EMA delays review of Flutiform MAA

Isotechnika receives scientific advice from EMA for voclosporin trial

Malaria vaccine RTS,S/ASO1E shows efficacy in African children

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...